Combination therapy for psoriasis in the United States

Journal of Drugs in Dermatology

Volumn 12, Issue 5, 2013, Pages 546-550

  Davis, Scott A ^a   Feldman, Steven R ^a,b,c  

^a Center for Dermatology Research   (United States)

^b Department of Pathology ^*  (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CLOBETASOL; CORTICOSTEROID; DESONIDE; DIFLORASONE; FLUOCINOLONE; FLUOCINONIDE; HYDROCORTISONE; METHOTREXATE; MOMETASONE FUROATE; TRIAMCINOLONE; ULOBETASOL PROPIONATE; VITAMIN D;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PSORIASIS; SCHOOL CHILD; UNITED STATES;

CALCITRIOL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEALTH CARE SURVEYS; HUMANS; METHOTREXATE; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; TIME FACTORS; UNITED STATES;

EID: 84877636100     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol. 2006;7(4):231-236.
2. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581-583.
3. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607-613.
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-407.
5. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957-962.
6. Li K, Armstrong AW. A review of health outcomes in patients with psoriasis. Dermatol Clin. 2012;30(1):61-72, viii.
7. Feldman SR. Practical Ways to Improve Patients' Treatment Outcomes. Winston- Salem, NC: Medical Quality Enhancement Corporation; 2009.
8. Serup J, Lindblad AK, Maroti M, et al. To follow or not to follow dermatological treatment-a review of the literature. Acta Derm Venereol. 2006;86(3):193-197.
9. Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327-332.
10. Feldman S, Housman T. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221-224.
11. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
12. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
13. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95-102.
14. Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol. 2002;46(4):557-559.
15. Dabade TS, Davis SA, Feldman SR. Phototherapy trends in dermatology. Presented at: 20th Annual Meeting of the Photomedicine Society; February 3, 2011; New Orleans, LA.
16. Feldman SR, Fleischer AB, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol. 2000;39(1):41-44.
17. Vogel SA, Yentzer B, Davis SA, Feldman SR, Cordoro KM. Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol. 2012;148(1):66-71.
18. Nolan BV, Levender MM, Davis SA, Feneran AN, Fleischer AB Jr, Feldman SR. Trends in the use of topical over the counter products in the management of dermatologic disease in the United States. Dermatol Online J. 2012;18(2):1.
19. Strowd LC, Yentzer BA, Fleischer AB Jr, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009;60(3):478-481.
20. Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39(2 Pt 3):S67-S73.
21. Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Schollgen I, Terris DD. Matching physicians' treatment recommendations to patients' treatment preferences is associated with improvement in treatment satisfaction [published online ahead of print May 28, 2012]. J Eur Acad Dermatol Venereol. doi:10.1111/j.1468-3083. 012.04569.x.
22. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther. 2006;19(4):224-236.
23. Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86(2):103-108.
24. Augustin M, Schafer I, Reich K, Glaeske G, Radtke M. Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3- guidelines. J Dtsch Dermatol Ges. 2011;9(10):833-838.
25. Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction [published online ahead of print July 25, 2012]? J Eur Acad Dermatol Venereol. doi:10.1111/j.1468-3083. 012.04656.x.